Lubiprostone for treating opioid induced constipation
Following on from information provided to NICE by the company in January 2019, the appraisal of Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain [646] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- Topic area
- Digestive system
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- 28 January 2014
- 1st appraisal committee meeting::
- 07 May 2014
Project Team
- Communications manager:
- TBC
- Project manager:
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Following on from information provided to NICE by the company in January 2019, the appraisal of Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain [646] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in January 2019, the appraisal of Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain [646] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 February 2021 | This guidance is no longer progressing because Takeda has discontinued lubiprostone (Amitiza). |
| 04 April 2014 | 7 May 2014 -Committee meeting for this appraisal topic has been cancelled. The appraisal is suspended because the regulatory timeline has changed due to the MHRA not granting a license for this indication. The appraisal topic will be rescheduled into the NICE work programme when the regulatory next steps are known.’ |
For further information on our processes and methods, please see our CHTE processes and methods manual